TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Remission defined as a CDAI of <150
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response defined as a fall in the CDAI by 100 points or more from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of carotid radial strain value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum tolerated dose (MTD) of SAIT301
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Effect Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Vitamin C and Tetrahydrobiopterin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCINF of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scratch Movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep Time
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Urinary Excretion of LY2606368 Radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fecal Excretion of LY2606368 Radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LY2606368 Radioactivity in Expired Air
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of female cercariae at which 100% volunteers show detectable Schistosoma mansoni circulating anodic antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Level of inflammatory biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Duration of ultrasound examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: innate and adaptive immunologic responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Flowrate of reinfusion of whole blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post transfusion hemolysis
Endpoint domain: Adverse events/effects
Primary endpoint: Resort to anesthesia
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Dosing Frequency of Analgesics for Treating Breakthrough Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline sleep quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Incidence of treatment related adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of dose limiting toxicities (DLT's)
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma biomarkers of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Mean Forced Expiratory Volume in 1st second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: CMV and EBV reactivation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Knee Injury and Osteoarthritis Outcome Score for patellofemoral pain and osteoarthritis (KOOS-PF)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Kujala's Anterior Pain Scale (AKPS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Short Form-36 health survey (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Stent Functionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fugl Meyer Assessment-upper Extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of Adjudicated Major or Clinically Relevant Non-Major (CRNM) Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of antigens or antibodies to Salmonella Typhi
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic value of MUAC in diagnosing SAM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in peak oxygen consumption (VO2peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in muscular mitochondrial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Recovery - 40 Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Disease-control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Freedom from clinically significant perforation
Endpoint domain: Adverse events/effects
Primary endpoint: Procedural and technical success without occurrence of clinically significant pulmonary embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reproducibility of rheological measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in diastolic heart function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in brain function assessed by functional MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in brain function assessed by electroencephalogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in white matter structural integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: BFI Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Trail Making Test B Score (TMT-B)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Symbol Digit Modalities Test Score (SDMT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Digit Span Test Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Neuromuscular block recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response of tumor evaluated by RECIST criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement of smoking hygiene practices
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: CT lung weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: CT lung recruitment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Claims paid for covered services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Successful Foley Catheter Removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of contamination of nurses' gloves with cytotoxic products
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients who experience dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Amount of Snack Foods Consumed Post-intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC0-2 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 2 h after drug administration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasticity of cortical and corticospinal neural circuits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasticity of spinal neural circuits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of Decline in Forced Expiratory Volume in One Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Total Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of nodal upstaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sexual intercourse onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of sexual partners
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of condoms and contraceptives
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Celiac Disease Quality of Life (CD-QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean change in ADAS-cog score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Distribution of CIBIC-plus Input
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Polysomnography (PSG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Wechsler Intelligence Scale for Children (WISC)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Occurrence of minor surgical site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of major surgical site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of capsular contracture
Endpoint domain: Adverse events/effects
Primary endpoint: Vaginal mucosal membrane response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in Lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of treatment delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of measurement of endometrial volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Acquisition of HIV infection
Endpoint domain: Mortality/survival
Primary endpoint: Grade 3 or 4 clinical or laboratory adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability as measured by session attendance
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Incidence of clinically relevant Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: COVID-19 status
Endpoint domain: Mortality/survival
Primary endpoint: AUC(0-120): Area Under the Plasma Concentration-Time Curve From Time 0 to 120 Hours Postdose for TAK-385
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum IgG antibody titers specific for the F-Protein antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Assessment of Safety
Endpoint domain: Adverse events/effects
Primary endpoint: Completion rate of nurse-led encounters
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 4-month Progression Free Survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: HbA1c at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hemodynamic fluctuations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Constipation Assessment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in endometriotic lesion size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change on the Liebowitz Social Anxiety Scale for Children and Adolescents
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Volumes of allogeneic blood products
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Volumes of cumulative drainage within 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volumes of cumulative drainage within 48 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volumes of cumulative drainage within 5 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients With Adverse Events Leading to Discontinuation of Trial Drug
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of early stage ovarian cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Serum VEGF-D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate as measured by RECIST criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants by Treatment Cohort With and Without a Benign Prostatic Hypertrophy (BPH) Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Provision of Addiction Treatments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Safety During Dose-Limiting Toxicity (DLT) Observation Period
Endpoint domain: Adverse events/effects
Primary endpoint: Type of stent (coated or uncoated)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma concentration ratios of metabolites to lofexidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in tissue-specific protein synthesis rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neurocognitive outcome scores (Z-scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative respiratory adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Type of anterior tooth movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of PRBC and blood products and coagulation factors transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Tube Erosion
Endpoint domain: Adverse events/effects
Primary endpoint: Change in bone mass density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain During Dressing Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variations of the ratio PP/HR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variations of SV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of immunohistochemical staining for Tn antigen and sialyl Tn antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of Forced Vital Capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of Maximal Inspiratory Pressure (MIP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of Maximal Expiratory Pressure (MEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Adherence to the Recommendations
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Baseline Standard Uptake Ratio Values (SUVr) of Florbetapir PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Baseline Retinal Amyloid Imaging (RAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline scores of the Dating Violence Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Modified Rankin Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Postoperative Pharyngolaryngeal Morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with device- or procedure-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Had Clinical Worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evidence of ovulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Overall response rate (complete clinical response and partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Methylation status of the PPAR gamma promoter region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Retention rate of canakinumab-treated patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Long-term safety and tolerability of canakinumab
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Total 3 Nasal Symptom Score (3TNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reports of daytime sleepiness
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: reports of quality of sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Immune Response Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Abstinent From Smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sum of pain intensity differences SPID
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity difference to baseline (PID12 min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity difference to baseline (PID120 min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Block success defined as loss of sensation to pinprick
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Motor blockade evaluated by strength of knee extension, thigh adduction, and ankle movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Biological markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in diastolic heart function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lymphocyte infiltration in orbital tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Graves' Orbitopathy (GO) activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral Performance Categories (CPC) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Aqueous Humour Cytokine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: intestinal parasitic infections
Endpoint domain: Adverse events/effects
Primary endpoint: Change in food waste
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in food consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in school meal satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: DNA methylation level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Risk of cisplatin-induced hearing loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of positive Candidiasis tests
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the curve (AUC) of percentage decrease in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Postoperative incisional pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Effectiveness of oral corticosteroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline in Development of NODAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: % change in PASI at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Area under the plasma concentration-time curve of caffeine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve of omeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve of s-warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve of dextromethorphan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score of KAP about oral health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Complete absence of dyspeptic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sniffin sticks score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICU-acquired weakness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants Achieving an Objective Response That Lasts at Least 4 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life of CML patients: EORTC QLQ-C30
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life